[HTML][HTML] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …

B Zou, VHF Lee, H Yan - BMC bioinformatics, 2018 - Springer
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - hub.hku.hk
BACKGROUND: Non-small cell lung cancer (NSCLC) with activating EGFR mutations,
especially exon 19 deletions and the L858R point mutation, is particularly responsive to …

[HTML][HTML] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

[HTML][HTML] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - bmcbioinformatics.biomedcentral …
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19
deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib …

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis

B Zou, VHF Lee, H Yan - BMC bioinformatics, 2018 - pubmed.ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - europepmc.org
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

[PDF][PDF] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - scholars.cityu.edu.hk
Background: Non-small cell lung cancer (NSCLC) with activating EGFR mutations,
especially exon 19 deletions and the L858R point mutation, is particularly responsive to …

[PDF][PDF] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …

B Zou, VHF Lee, H Yan - 2018 - bcc.ee.cityu.edu.hk
Background: Non-small cell lung cancer (NSCLC) with activating EGFR mutations,
especially exon 19 deletions and the L858R point mutation, is particularly responsive to …

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis

B Zou, VHF Lee, H Yan - BMC Bioinformatics, 2018 - go.gale.com
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis

B Zou, VHF Lee, H Yan - 2018 - agris.fao.org
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …